1-Methoxymethyl-2,4-dimethyl-benzene | 18922-09-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Methoxymethyl-2,4-dimethyl-benzene
• 英文别名: 1-(Methoxymethyl)-2,4-dimethylbenzene
• CAS: 18922-09-3
• 化学式: C₁₀H₁₄O
• 分子量: 150.221
• InChiKey: VDPXDWRUUZQNNH-UHFFFAOYSA-N

物化性质

• 沸点：
  200.995±9.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  0.932±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Methoxymethyl-2,4-dimethyl-benzene 生成 5-氰基邻苯二甲酰亚胺
  参考文献：
  名称：

  GABDULINA L. F.; SEMBAEV D. X.; CYBOPOB B. V., KAZSSR GYLYM AKAD. XABARLARY, IZV. AN KAZ CCP. CEP. XIM. 1978, HO 6, 41-4+

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(氯甲基)-2,4-二甲苯 、 甲醇 、 sodium hydroxide 以82%的产率得到
  参考文献：
  名称：

  GABDULINA L. F.; SEMBAEV D. X.; CYBOPOB B. V., KAZSSR GYLYM AKAD. XABARLARY, IZV. AN KAZ CCP. CEP. XIM. 1978, HO 6, 41-4+

  摘要：

  DOI：

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
  申请人：Dow AgroSciences LLC

  公开号：US20170066757A1

  公开（公告）日：2017-03-09

  This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

  这份披露涉及具有对节肢动物门、软体动物门和线虫门害虫的杀虫效用的分子领域，用于生产此类分子的工艺，用于此类工艺的中间体，含有此类分子的杀虫组合物，以及使用此类杀虫组合物对抗此类害虫的过程。这些杀虫组合物可以用作杀螨剂、杀虫剂、杀螨剂、杀软体动物剂和杀线虫剂，例如。本文件披露了具有以下公式（“公式一”）的分子。
• [EN] OCULOSELECTIVE DRUGS AND PRODRUGS<br/>[FR] MEDICAMENTS ET PROMEDICAMENTS OCULOSELECTIFS
  申请人：OTHERA PHARMACEUTICALS INC

  公开号：WO2005115375A1

  公开（公告）日：2005-12-08

  Compounds of the following formula are disclosed: wherein R1 and R2 are each independently H, W, or a phenoxyl protecting group; and R4is H or W, provided that at least one of R1, R2, and R4 is W; R3 is hydrogen, straight chain or branched C1-C10 alkyl, cycloalkyl, amino, C1-C10 alkoxy, -NHC(=O)Ra, or -C(=O)N(H)Ra; Ra is alkyl, aryl, or heterocyclyl; Z is -0-, -O(C=O)-, or NH(C=O)-, wherein when Z is -0-, R5 is H, straight chain or branched C1-C10 alkyl, cycloalkyl, cycloalkyl substituted with at least one straight or branched C1-C10 alkyl, CI-Clo alkoxyalkyl, amino, benzyl, tetrahydrofuranyl, dihydrofuranyl, furanyl, morpholinyl, piperidinyl, tetrahydropyranyl, dioxolanyl, 2,2-dimethyl dioxolanyl, dioxanyl, pyrrolyl, pyrrolsdinyl, tetrahydrooxazolyl, dihydrooxazolyl, phenyl, or phenyl substituted with CI-Clo alkyl, C1-C10 alkoxy, or halo; and W is:, wherein each R6 is independently H, straight chain or branched C1-C10 alkyl, or straight chain or branched Cl-C10 alkoxyalkyl; and R7 is alkyl, cycloalkyl, aryl, or aralkyl; and wherein when Z is -O(C=O)-, R5 is straight chain or branched C1-C10 alkyl, cycloalkyl, cycloalkyl substituted with at least one straight or branched C1-C10 alkyl, CI-CIO alkoxyalkyl, amino, benzyl, tetrahydrofuranyl, dihydrofuranyl, furanyl, morpholinyl, piperidinyl, tetrahydropyranyl, dioxolanyl, 2,2-dimethyl dioxolanyl, dioxanyl, pyrrolyl, pyrrolidinyl, tetrahydrooxazolyl, dihydrooxazolyl, phenyl, or phenyl substituted with Cl-C10 alkyl, C1-C10 alkoxy, or halo; and W is: , wherein each R6 is independently H, straight chain or branched CI-C to alkyl, or straight chain or branched C,-C to alkoxyalkyl; and R7 is alkyl, cycloalkyl, aryl, or aralkyl; and wherein when Z is-NH(C=O)-, R5 is straight chain or branched C1 -C10 alkyl, cycloalkyl, cycloalkyl substituted with at least one straight or branched C1-C10 alkyl, CI-CIO alkoxyalkyl, amino, benzyl, tetrahydrofuranyl, dihydrofuranyl, furanyl, morpholinyl, piperidinyl, tetrahydropyranyl, &oxolanyl, 2,2-dimethyl dioxolanyl, dioxanyl, pyrrolyl, pyrrolidinyl, tetrahydrooxazolyl, dihydrooxazolyl, phenyl, or phenyl substituted with C1-C10 alkyl, C1-C10 alkoxy, or halo; and W is: ; wherein each R6 is independently H, straight chain or branched C1 -C to alkyl, or straight chain or branched C,-Clo alkoxyalkyl. Methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of treating patients by administration of the pharmaceutical compositions, are also disclosed.

  公开了以下式子的化合物：其中R1和R2分别独立地为H、W或苯氧基保护基；R4为H或W，但至少其中一个为W；R3为氢、直链或支链C1-C10烷基、环烷基、氨基、C1-C10烷氧基、-NHC（=O）Ra或-C（=O）N（H）Ra；Ra为烷基、芳基或杂环基；Z为-0-、-O（C=O）-或NH（C=O）-，其中当Z为-0-时，R5为H、直链或支链C1-C10烷基、环烷基、至少含有一个直链或支链C1-C10烷基的环烷基、CI-Clo烷氧基烷基、氨基、苯甲基、四氢呋喃基、二氢呋喃基、呋喃基、吗啉基、哌啶基、四氢吡喃基、二氢二氧杂环基、2,2-二甲基二氧杂环基、二氧杂环基、吡咯基、吡咯啉基、四氢噁唑基、二氢噁唑基、苯基或被CI-Clo烷基、C1-C10烷氧基或卤素取代的苯基；W为：其中每个R6独立地为H、直链或支链C1-C10烷基或直链或支链Cl-C10烷氧基烷基；R7为烷基、环烷基、芳基或芳烷基；当Z为-O（C=O）-时，R5为直链或支链C1-C10烷基、环烷基、至少含有一个直链或支链C1-C10烷基的环烷基、CI-CIO烷氧基烷基、氨基、苯甲基、四氢呋喃基、二氢呋喃基、呋喃基、吗啉基、哌啶基、四氢吡喃基、二氢二氧杂环基、2,2-二甲基二氧杂环基、二氧杂环基、吡咯基、吡咯啉基、四氢噁唑基、二氢噁唑基、苯基或被CI-C10烷基、C1-C10烷氧基或卤素取代的苯基；W为：其中每个R6独立地为H、直链或支链CI-C to烷基或直链或支链C,-C to烷氧基烷基；R7为烷基、环烷基、芳基或芳烷基；当Z为-NH（C=O）-时，R5为直链或支链C1-C10烷基、环烷基、至少含有一个直链或支链C1-C10烷基的环烷基、CI-CIO烷氧基烷基、氨基、苯甲基、四氢呋喃基、二氢呋喃基、呋喃基、吗啉基、哌啶基、四氢吡喃基、二氢二氧杂环基、2,2-二甲基二氧杂环基、二氧杂环基、吡咯基、吡咯啉基、四氢噁唑基、二氢噁唑基、苯基或被C1-C10烷基、C1-C10烷氧基或卤素取代的苯基；W为：其中每个R6独立地为H、直链或支链C1-C to烷基或直链或支链C,-Clo烷氧基烷基。还公开了制备这些化合物的方法、包含这些化合物的药物组成物以及通过给患者给药这些药物组成物的治疗方法。